Evergreen Theragnostics
Springfield, NJ
Program data pending ClinicalTrials.gov matching
60.0
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (9)
○ EMA GMP
○ MHRA GMP
Quick Facts: Evergreen Theragnostics
- Signal Score
- 60.0/100
- Quality Compliance
- Assessment pending
- Headquarters
- Springfield, NJ
- Modalities
- Ac-225, At-211, Pb-212, Th-227, Lu-177, Alpha emitter radiopharmaceuticals, Clinical and Commercial GMP Manufacturing
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About Evergreen Theragnostics
Auto-created by AI matchmaker. Data verification pending.
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesAc-225, At-211, Pb-212, Th-227, Lu-177, Alpha emitter radiopharmaceuticals, Clinical and Commercial GMP Manufacturing
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
60.0
Broad modality coverage (7 modalities)
Source: SEC EDGAR, press monitoring, company profiles
Profile-based capacity assessment
Recent Press9 articles
Broad modality coverage (7 modalities)
Recent News 9 articles
LNTH: Evergreen Acquisition Promotes Future Innovation - scr.zacks.com
Lantheus acquires radiopharma CDMO Evergreen for up to $1bn - Pharmaceutical Technology
Lantheus to buy radiopharma CDMO Evergreen Theragnostics for $250M upfront - Medical Marketing and Media
Lantheus Holdings to Acquire Evergreen Theragnostics - Contract Pharma
Lantheus lays out $250M+ to get its hands on radiopharma developer and CDMO Evergreen - Fierce Pharma
Lantheus to Acquire Evergreen Theragnostics for Upfront Payment of $250 Million to Drive Strategic Evolution into Fully Integrated Radiopharmaceutical Leader - PR Newswire
Evergreen Theragnostics Completes $26M Capital Raise to Advance Novel Radiopharmaceutical Pipeline into the Clinic, Prepare for First Commercial Product Launch, and Expand Industry-Leading CDMO Services - PR Newswire
Evergreen Theragnostics Raises $26M in Capital to Aid Commercialization Efforts for the Ga-68 DOTATOC Diagnostic Kit - Pharmaceutical Commerce
Evergreen Theragnostics Completes $15M Series B, Launches Discovery Unit, and Prepares Ga-68 DOTATOC Supply Chain - PR Newswire
Frequently Asked Questions About Evergreen Theragnostics
What is Evergreen Theragnostics's CDMO Signal Score?
Evergreen Theragnostics has a Signal Score of 60/100, based on quality, operations, financial stability, and capacity data.
Evaluating Evergreen Theragnostics for a manufacturing program?
Use the free AI matchmaker to compare Evergreen Theragnostics against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.